Document is current
Any future updates will be listed below
-
Authors
Río, Paula
Navarro, Susana
Wang, Wei
Sánchez-Domínguez, Rebeca
Pujol, Roser M.
Segovia, José C.
Bogliolo, Massimo
Merino, Eva
Wu, Ning
Salgado, Rocío
Lamana, María L.
Yañez, Rosa M.
Casado, José A.
Giménez, Yari
Román-Rodríguez, Francisco J.
Álvarez, Lara
Alberquilla, Omaira
Raimbault, Anna
Guenechea, Guillermo
Lozano, M. Luz
Cerrato, Laura
Hernando, Miriam
Gálvez, Eva
Hladun, Raquel
Giralt, Irina
Barquinero, Jordi
Galy, Anne
García de Andoín, Nagore
López, Ricardo
Catalá, Albert
Schwartz, Jonathan D.
Surrallés, Jordi
Soulier, Jean
Schmidt, Manfred
Díaz de Heredia, Cristina
Sevilla, Julián https://orcid.org/0000-0002-6852-1860
Bueren, Juan A. https://orcid.org/0000-0002-3228-7013
- License Information
-
More Information
Article History
Received: 22 June 2018
Accepted: 18 July 2019
First Online: 9 September 2019
Competing interests
: The Hematopoietic Innovative Therapies division at CIEMAT receives funding and has licensed the PGK-FANCA-WPRE* lentiviral vector to Rocket Pharmaceuticals. J.A.B., J.Sevilla and J.C.S. are consultants for Rocket Pharmaceuticals. J.D.S. is Medical Director of Rocket Pharmaceuticals. P.R., S.N., J.A.C., J.C.S., J.Sevilla, G.G. and J.A.B. are inventors on patents on lentiviral vectors filed by CIEMAT, CIBERER and Fundación Jiménez Díaz, and may be entitled to receive financial benefits from the licensing of such patents. M.S. is co-founder and CEO of GeneWerk. W.W. is an employee of GeneWerk. The remaining authors declare no competing interests.
